Search Results - "Hourd, Paul"

Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics by Hourd, Paul, Williams, David J

“…Highlights • Converging technology innovations underlie the next generation of cell therapeutics. • Future perspectives within the PSC therapeutic space are…”
Get full text

Precision manufacturing for clinical-quality regenerative medicines by Williams, David J., Thomas, Robert J., Hourd, Paul C., Chandra, Amit, Ratcliffe, Elizabeth, Liu, Yang, Rayment, Erin A., Archer, J. Richard

“…Innovations in engineering applied to healthcare make a significant difference to people's lives. Market growth is guaranteed by demographics. Regulation and…”
Get full text

A quality-by-design approach to risk reduction and optimization for human embryonic stem cell cryopreservation processes by Mitchell, Peter D, Ratcliffe, Elizabeth, Hourd, Paul, Williams, David J, Thomas, Robert J

“…It is well documented that cryopreservation and resuscitation of human embryonic stem cells (hESCs) is complex and ill-defined, and often suffers poor cell…”
Get more information

Manufacture of a human mesenchymal stem cell population using an automated cell culture platform by THOMAS, Robert James, CHANDRA, Amit, YANG LIU, HOURD, Paul C, CONWAY, Paul P, WILLIAMS, David J

“…Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell-based constructs as therapeutic products for a wide range of…”
Get full text

Application of response surface methodology to maximize the productivity of scalable automated human embryonic stem cell manufacture by Ratcliffe, Elizabeth, Hourd, Paul, Guijarro-Leach, Juan, Rayment, Erin, Williams, David J, Thomas, Robert J

“…Commercial regenerative medicine will require large quantities of clinical-specification human cells. The cost and quality of manufacture is notoriously…”
Get more information

Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability by Hourd, Paul, Ginty, Patrick, Chandra, Amit, Williams, David J

“…Abstract Manufacturing of more-than-minimally manipulated autologous cell therapies presents a number of unique challenges driven by complex supply logistics…”
Get full text

A 3D bioprinting exemplar of the consequences of the regulatory requirements on customized processes by Hourd, Paul, Medcalf, Nicholas, Segal, Joel, Williams, David J

“…Computer-aided 3D printing approaches to the industrial production of customized 3D functional living constructs for restoration of tissue and organ function…”
Get full text

The management of risk and investment in cell therapy process development: a case study for neurodegenerative disease by Sebastian, Sujith, Hourd, Paul, Chandra, Amit, Williams, David J, Medcalf, Nicholas

“…Cell-based therapies must achieve clinical efficacy and safety with reproducible and cost-effective manufacturing. This study addresses process development…”
Get full text

Success in healthcare technology businesses: Coordinating the value milestones of new product introduction, financial stakeholders and business growth by Hourd, Paul C, Williams, David J

“…To get medical products to market, pharmaceutical, biological product and medical device businesses must successfully progress along a multidimensional path…”
Get full text

Human cell culture process capability: a comparison of manual and automated production by Liu, Yang, Hourd, Paul, Chandra, Amit, Williams, David J.

“…Cell culture is one of the critical bioprocessing steps required to generate sufficient human‐derived cellular material for most cell‐based therapeutic…”
Get full text

Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products by Hourd, Paul, Chandra, Amit, Alvey, David, Ginty, Patrick, McCall, Mark, Ratcliffe, Elizabeth, Rayment, Erin, Williams, David J

“…Academic centers, hospitals and small companies, as typical development settings for UK regenerative medicine assets, are significant contributors to the…”
Get more information

Mesenchymal stem cell isolation from human umbilical cord tissue: understanding and minimizing variability in cell yield for process optimization by Iftimia-Mander, Andreea, Hourd, Paul, Dainty, Roger, Thomas, Robert J

“…Human tissue banks are a potential source of cellular material for the nascent cell-based therapy industry; umbilical cord (UC) tissue is increasingly…”
Get more information

Improving umbilical cord blood processing to increase total nucleated cell count yield and reduce cord input wastage by managing the consequences of input variation by Naing, May Win, Gibson, Daniel A, Hourd, Paul, Gomez, Susana G, Horton, Roger B.V, Segal, Joel, Williams, David J

“…Abstract Background aims With the rising use of umbilical cord blood (UCB) as an alternative source of hematopoietic stem cells, storage inventories of UCB…”
Get full text

Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14-15 September 2015 by Williams, David J, Archer, Richard, Archibald, Peter, Bantounas, Ioannis, Baptista, Ricardo, Barker, Roger, Barry, Jacqueline, Bietrix, Florence, Blair, Nicholas, Braybrook, Julian, Campbell, Jonathan, Canham, Maurice, Chandra, Amit, Foldes, Gabor, Gilmanshin, Rudy, Girard, Mathilde, Gorjup, Erwin, Hewitt, Zöe, Hourd, Paul, Hyllner, Johan, Jesson, Helen, Kee, Jasmin, Kerby, Julie, Kotsopoulou, Nina, Kowalski, Stanley, Leidel, Chris, Marshall, Damian, Masi, Louis, McCall, Mark, McCann, Conor, Medcalf, Nicholas, Moore, Harry, Ozawa, Hiroki, Pan, David, Parmar, Malin, Plant, Anne L, Reinwald, Yvonne, Sebastian, Sujith, Stacey, Glyn, Thomas, Robert J, Thomas, Dave, Thurman-Newell, Jamie, Turner, Marc, Vitillo, Loriana, Wall, Ivan, Wilson, Alison, Wolfrum, Jacqueline, Yang, Ying, Zimmerman, Heiko

“…This paper summarizes the proceedings of a workshop held at Trinity Hall, Cambridge to discuss comparability and includes additional information and references…”
Get full text

Regenerative medicine, resource and regulation: lessons learned from the remedi project by Ginty, Patrick J, Rayment, Erin A, Hourd, Paul, Williams, David J

“…The successful commercialization of regenerative medicine products provides a unique challenge to the manufacturer owing to a lack of suitable…”
Get more information